Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N. lactamica Nasal Inoculation in Malian Adults
NCT04665791Phase 1Completed
- Sponsor
- Center for Vaccine Development–Mali
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Neisseria lactamica in meningococcal meningitis, sponsored by Center for Vaccine Development–Mali. Primary endpoints: Nasopharyngeal colonisation with Neisseria species at 6 months, Information about symptoms at 6 months and 5 more. Started Mar 2021; status: completed.
02
Drugs
Neisseria lactamica
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT04665791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665791.